Papillary Thyroid Carcinoma in a Patient with Psoriasis Treated with Secukinumab

IntroductIonPsoriasis is a chronic, immune-mediated inflammatory disease characterized by erythematous, scaly plaques.It is associated with a high prevalence of comorbidities, including other autoimmune diseases and malignancies.Chronic inflammation related to psoriasis, as well as immunosuppressive, immunomodulatory, and phototherapy treatments, may contribute to the development of malignancies.Treatment of moderate-to-severe psoriasis often requires systemic therapy, including biologic agents [1].Secukinumab is an interleukin-17A inhibitor that has demonstrated significant efficacy and a rapid onset of action in the treatment of moderate-to-severe psoriasis [2]. objectIveWe report a case of papillary thyroid carcinoma in a patient with psoriasis treated with secukinumab. case reportA 35-year-old man had been followed for psoriasis vulgaris since 2018.He presented with scaly erythematous plaques on the body and scalp.His initial Psoriasis Area and Severity Index (PASI) score was 7.6.The symptoms had started 5 years before his first visit, during which time he had only used topical treatments.